NEW YORK, USA — April 1, 2026
Hoth Therapeutics, Inc. announced that its investigational therapy HT-001 has successfully met the primary efficacy endpoint in an interim Phase 2 clinical analysis, while also receiving regulatory approval in Hungary to expand its clinical trial into Europe. The study demonstrated that patients achieved an ARIGA rash severity score of ≤1 by week six, highlighting strong clinical efficacy in treating dermatologic toxicities associated with cancer therapies, particularly those linked to epidermal growth factor receptor (EGFR) inhibitors.
Clinical Data Shows Strong Efficacy and Patient Benefit
The interim analysis revealed that HT-001 delivered clinically meaningful improvements across multiple endpoints, with more than 65% of patients reporting significant reductions in pain and itching, key symptoms that often impact quality of life in oncology patients. These results underscore the therapy’s ability to provide targeted symptom relief while maintaining strong efficacy outcomes, positioning HT-001 as a promising candidate in oncology supportive care.
Importantly, the study reported zero disruptions to ongoing EGFR cancer treatments, with no patients requiring dose reductions or discontinuation of their primary cancer therapy. This finding is particularly significant, as dermatologic toxicities frequently lead to treatment interruptions or modifications, which can negatively affect overall cancer outcomes. HT-001’s ability to maintain continuity of life-saving therapies represents a critical advantage over existing treatment options.
Favorable Safety Profile and Targeted Drug Delivery
Advertisement
HT-001 demonstrated a strong safety and tolerability profile, with no treatment discontinuations reported during the study. Pharmacokinetic analysis further showed that the therapy achieves approximately 99% lower systemic exposure compared to oral therapies, indicating a targeted delivery mechanism that minimizes systemic side effects while maximizing local therapeutic impact.
This localized approach is particularly important in oncology settings, where patients are often managing multiple therapies and are at increased risk of drug-drug interactions and cumulative toxicity. By reducing systemic exposure, HT-001 offers a safer and more effective solution for managing treatment-related dermatologic complications, addressing a significant unmet need in cancer care.
Regulatory Expansion Supports Global Clinical Development
Following the positive interim results, Hoth Therapeutics has secured regulatory approval in Hungary, enabling the expansion of its Phase 2 clinical trial into Europe. Additional regulatory approvals are anticipated in Spain and Poland, while new clinical sites are expected to be activated in the United States, accelerating patient enrollment and data generation.
This expansion reflects growing regulatory confidence in HT-001’s clinical potential and safety profile, supporting broader evaluation across diverse patient populations. From a cGxP perspective, the development highlights the importance of robust clinical trial execution (GCP), regulatory alignment, and global study scalability in advancing innovative therapies toward potential approval.
Industry Impact and Future Outlook
The success of HT-001 underscores the increasing importance of supportive care therapies in oncology, where improving patient quality of life is a critical component of comprehensive treatment strategies. As cancer therapies become more advanced, the need for effective management of treatment-related side effects continues to grow.
By combining strong clinical efficacy, targeted delivery, and minimal systemic exposure, HT-001 has the potential to become a differentiated therapy in dermatologic oncology care, addressing a significant gap in current treatment options. The ongoing expansion of its clinical program positions Hoth Therapeutics to play a key role in advancing patient-centric innovation and next-generation supportive care solutions in the biopharmaceutical industry.
Source: Hoth Therapeutics press release
